Latest filing published 06 Jan 2020 for Apollo Endosurgery, Inc..
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
James W. Traweek Jr.: trading record in brief
This profile gathers the share dealings of James W. Traweek Jr. across 2 companies, led by Reata Pharmaceuticals Inc and Apollo Endosurgery, Inc. The record holds 49 filings, for trades running from 1 June 2016 to 2 January 2020.
Every open-market trade on record is a purchase: 36 purchases worth €41.7M, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price.
In size, the median ticket on the buying side is €362k. Clusters matter here: 36 out of 36 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.
The newest entry dates from 6 January 2020: a transaction, in Apollo Endosurgery, Inc. The most recent open-market purchase was published on 18 November 2019, 2,547 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to James W. Traweek Jr.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 3,811 sharesClass A common stockSEC:0001140361-20-000333:0
- 15,244 sharesClass A common stockSEC:0001140361-20-000333:1
- 38,108 sharesClass A common stockSEC:0001140361-20-000333:2
- 30,000 sharesClass A common stockSEC:0000905148-20-000001:0
- 30,478 sharesClass A common stockSEC:0000905148-19-001035:0
- 40,218 shares@ US$183.0053.5% of flowClass A common stockSEC:0000905148-19-001003:0Canonical exit: 16 Feb 2020 (T+90)
- 26,174 shares@ US$57.9310.7% of flowClass A common stockSEC:0000905148-18-000922:0Canonical exit: 10 Mar 2019 (T+90)
- 1,078 shares@ US$58.620.4% of flowClass A common stockSEC:0000905148-18-000922:1Canonical exit: 10 Mar 2019 (T+90)
- 29,347 shares@ US$59.5312.3% of flowClass A common stockSEC:0000905148-18-000922:2Canonical exit: 10 Mar 2019 (T+90)
- 52,809 shares@ US$60.0722.4% of flowClass A common stockSEC:0000905148-18-000922:3Canonical exit: 11 Mar 2019 (T+90)
- 1,418 shares@ US$59.900.6% of flowClass A common stockSEC:0000905148-18-000922:4Canonical exit: 12 Mar 2019 (T+90)
- 17,000 shares@ US$28.471.0% of flowClass A common stockSEC:0001140361-17-047825:0Canonical exit: 29 Mar 2018 (T+90)
- 12,000 shares@ US$26.060.6% of flowClass A common stockSEC:0001140361-17-047654:0Canonical exit: 26 Mar 2018 (T+90)
- 15,000 shares@ US$25.830.8% of flowClass A common stockSEC:0001140361-17-047654:1Canonical exit: 27 Mar 2018 (T+90)
- 200 shares@ US$26.100.0% of flowClass A common stockSEC:0001140361-17-047654:2Canonical exit: 28 Mar 2018 (T+90)
- 121,425 shares@ US$24.886.2% of flowClass A common stockSEC:0000905148-17-000941:0Canonical exit: 13 Mar 2018 (T+90)
- 300 shares@ US$23.980.0% of flowClass A common stockSEC:0000905148-17-000941:1Canonical exit: 13 Mar 2018 (T+90)
- 78,275 shares@ US$24.653.9% of flowClass A common stockSEC:0000905148-17-000941:2Canonical exit: 14 Mar 2018 (T+90)
- 742,289 sharesClass A common stockSEC:0000905148-17-000626:0
- 9,392 shares@ US$21.720.5% of flowClass A common stockSEC:0000905148-17-000018:0Canonical exit: 30 Mar 2017 (T+90)
- 164,753 shares@ US$22.998.7% of flowClass A common stockSEC:0000905148-16-002141:0Canonical exit: 16 Mar 2017 (T+90)
- 6,189 shares@ US$21.370.3% of flowClass A common stockSEC:0000905148-16-002129:0Canonical exit: 14 Mar 2017 (T+90)
- 2,700 shares@ US$22.050.1% of flowClass A common stockSEC:0000905148-16-002129:1Canonical exit: 15 Mar 2017 (T+90)
- 58,600 shares@ US$16.212.0% of flowClass A common stockSEC:0000905148-16-001851:0Canonical exit: 14 Nov 2016 (T+90)
- 144,058 shares@ US$17.265.3% of flowClass A common stockSEC:0000905148-16-001851:1Canonical exit: 15 Nov 2016 (T+90)
25 of 34 declarations
